Primecap Management Co. CA Sells 353,394 Shares of LivaNova PLC (NASDAQ:LIVN)

Primecap Management Co. CA reduced its position in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 5.9% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 5,627,806 shares of the company's stock after selling 353,394 shares during the period. Primecap Management Co. CA owned about 10.36% of LivaNova worth $295,685,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Intech Investment Management LLC increased its position in LivaNova by 80.4% in the 3rd quarter. Intech Investment Management LLC now owns 15,815 shares of the company's stock valued at $831,000 after acquiring an additional 7,049 shares in the last quarter. Segall Bryant & Hamill LLC bought a new position in LivaNova in the third quarter valued at approximately $2,127,000. Simplify Asset Management Inc. lifted its stake in LivaNova by 67.5% in the third quarter. Simplify Asset Management Inc. now owns 14,346 shares of the company's stock valued at $754,000 after buying an additional 5,782 shares in the last quarter. Victory Capital Management Inc. lifted its stake in LivaNova by 16.6% in the third quarter. Victory Capital Management Inc. now owns 935,102 shares of the company's stock valued at $49,130,000 after buying an additional 133,401 shares in the last quarter. Finally, GSA Capital Partners LLP bought a new position in LivaNova in the third quarter valued at approximately $292,000. 97.64% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on LIVN. The Goldman Sachs Group began coverage on shares of LivaNova in a research report on Friday, October 4th. They issued a "buy" rating and a $65.00 price objective on the stock. Needham & Company LLC reiterated a "buy" rating and issued a $75.00 price objective on shares of LivaNova in a report on Tuesday, November 12th. Baird R W upgraded shares of LivaNova from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, September 17th. Stifel Nicolaus upped their price target on shares of LivaNova from $70.00 to $72.00 and gave the company a "buy" rating in a research note on Thursday, July 25th. Finally, Mizuho decreased their price target on shares of LivaNova from $80.00 to $70.00 and set an "outperform" rating on the stock in a research note on Thursday, October 31st. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, LivaNova presently has an average rating of "Buy" and an average target price of $69.17.

LivaNova Trading Down 2.6 %

LIVN opened at $50.05 on Thursday. The stock has a market capitalization of $2.72 billion, a price-to-earnings ratio of 119.17 and a beta of 1.01. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. LivaNova PLC has a twelve month low of $42.75 and a twelve month high of $64.47. The company has a 50-day simple moving average of $51.96 and a 200 day simple moving average of $52.70.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.